Pharma Journalist 8778 posts 0 comments

Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have…
Read More...

Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc.…
Read More...

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA (erdafitinib) for the treatment…
Read More...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases,…
Read More...

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the U.S. Food and Drug Administration (FDA) has granted Fast…
Read More...

BridgeBio Pharma, Inc. (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced strategic financing from Blue Owl…
Read More...

Halozyme Therapeutics, Inc. announced that argenx received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for VYVDURA (efgartigimod alfa and hyaluronidase-qvfc)…
Read More...

Roche announced that the European Commission has granted marketing authorisation for Tecentriq SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved HYQVIA  for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance…
Read More...

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved CASGEVY (exagamglogene autotemcel ), a CRISPR/Cas9 gene-edited cell therapy,…
Read More...